Idiopathic pulmonary fibrosis: Disease mechanisms and drug development

P Spagnolo, JA Kropski, MG Jones, JS Lee… - Pharmacology & …, 2021 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause
characterized by relentless scarring of the lung parenchyma leading to reduced quality of life …

Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy

P Spagnolo, TM Maher, L Richeldi - Pharmacology & therapeutics, 2015 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial
pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades …

Pharmacological treatment of idiopathic pulmonary fibrosis: current approaches, unsolved issues, and future perspectives

M Kreuter, F Bonella, M Wijsenbeek… - BioMed research …, 2015 - Wiley Online Library
Idiopathic pulmonary fibrosis (IPF) is a devastating condition with a 5‐year survival of
approximately 20%. The disease primarily occurs in elderly patients. IPF is a highly …

[HTML][HTML] Idiopathic pulmonary fibrosis: an update on pathogenesis

Q Mei, Z Liu, H Zuo, Z Yang, J Qu - Frontiers in Pharmacology, 2022 - frontiersin.org
Idiopathic pulmonary fibrosis (IPF) is a progressive, lethal fibrotic lung disease that occurs
primarily in middle-aged and elderly adults. It is a major cause of morbidity and mortality …

Idiopathic pulmonary fibrosis: an update

P Spagnolo, N Sverzellati, G Rossi, A Cavazza… - Annals of …, 2015 - Taylor & Francis
Idiopathic pulmonary fibrosis (IPF) is the most common and lethal form of idiopathic
interstitial pneumonia. The disease, which occurs primarily in middle-aged and older adults …

[HTML][HTML] Research progress in the molecular mechanisms, therapeutic targets, and drug development of idiopathic pulmonary fibrosis

H Ma, X Wu, Y Li, Y Xia - Frontiers in Pharmacology, 2022 - frontiersin.org
Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease. Recent studies have
identified the key role of crosstalk between dysregulated epithelial cells, mesenchymal …

Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches

DS Glass, D Grossfeld, HA Renna, P Agarwala… - Respiratory …, 2020 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease with high mortality that
commonly occurs in middle-aged and older adults. IPF, characterized by a decline in lung …

The therapy of idiopathic pulmonary fibrosis: what is next?

V Somogyi, N Chaudhuri, SE Torrisi… - European …, 2019 - Eur Respiratory Soc
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung
disease, characterised by progressive scarring of the lung and associated with a high …

Update on therapeutic management of idiopathic pulmonary fibrosis

A Tzouvelekis, F Bonella… - Therapeutics and clinical …, 2015 - Taylor & Francis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive diffuse parenchymal lung
disease of unknown origin, with a mortality rate exceeding that of many cancers. The …

[HTML][HTML] Challenges for clinical drug development in pulmonary fibrosis

ES White, M Thomas, S Stowasser… - Frontiers in …, 2022 - frontiersin.org
Pulmonary fibrosis is a pathologic process associated with scarring of the lung interstitium.
Interstitial lung diseases (ILDs) encompass a large and heterogenous group of disorders, a …